143 related articles for article (PubMed ID: 18559410)
21. "Clinical benefit rate" in phase 2 gynecologic cancer trials: implying more than the data support?
Markman M
Gynecol Oncol; 2010 May; 117(2):348-9. PubMed ID: 20167354
[No Abstract] [Full Text] [Related]
22. Quality of life in clinical cancer trials: experience and perspective of the European Organization for Research and Treatment of Cancer.
Kiebert GM; Kaasa S
J Natl Cancer Inst Monogr; 1996; (20):91-5. PubMed ID: 8750477
[No Abstract] [Full Text] [Related]
23. Multinomial phase II trial designs.
Freidlin B; Dancey J; Korn EL; Zee B; Eisenhauer E
J Clin Oncol; 2002 Jan; 20(2):599. PubMed ID: 11786592
[No Abstract] [Full Text] [Related]
24. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
25. A Bayesian predictive two-stage design for phase II clinical trials.
Sambucini V
Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
[TBL] [Abstract][Full Text] [Related]
26. How to deal with multiple endpoints in clinical trials.
Neuhäuser M
Fundam Clin Pharmacol; 2006 Dec; 20(6):515-23. PubMed ID: 17109645
[TBL] [Abstract][Full Text] [Related]
27. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
[TBL] [Abstract][Full Text] [Related]
28. An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies.
Jones CL; Holmgren E
Contemp Clin Trials; 2007 Sep; 28(5):654-61. PubMed ID: 17412647
[TBL] [Abstract][Full Text] [Related]
29. Is response rate relevant to the phase II trial design of targeted agents?
Dowlati A; Fu P
J Clin Oncol; 2008 Mar; 26(8):1204-5. PubMed ID: 18285601
[No Abstract] [Full Text] [Related]
30. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
Penel N; Clisant S; Lefebvre JL; Adenis A
J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
[No Abstract] [Full Text] [Related]
31. Single-arm phase II trial design under parametric cure models.
Wu J
Pharm Stat; 2015; 14(3):226-32. PubMed ID: 25846141
[TBL] [Abstract][Full Text] [Related]
32. Bayesian two-stage designs for phase II clinical trials.
Tan SB; Machin D
Stat Med; 2006 Oct; 25(19):3407-8. PubMed ID: 16847890
[No Abstract] [Full Text] [Related]
33. Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
Chabner BA; Ratain MJ
Clin Cancer Res; 2007 Nov; 13(21):6540. PubMed ID: 17975169
[No Abstract] [Full Text] [Related]
34. Single-arm Phase II cancer survival trial designs.
Wu J
J Biopharm Stat; 2016; 26(4):644-56. PubMed ID: 26098141
[TBL] [Abstract][Full Text] [Related]
35. Study design aspects and inter-subject variability in longitudinal clinical phase II dose-finding trials.
Kennes LN; Volkers G; Kralidis G
Pharm Stat; 2019 Mar; 18(2):248-259. PubMed ID: 30623569
[TBL] [Abstract][Full Text] [Related]
36. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
37. An efficient multi-stage, single-arm Phase II futility design for ALS.
Palesch YY; Tilley BC
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():55-6. PubMed ID: 15512874
[No Abstract] [Full Text] [Related]
38. Phase II trial design with growth modulation index as the primary endpoint.
Wu J; Chen L; Wei J; Weiss H; Miller RW; Villano JL
Pharm Stat; 2019 Mar; 18(2):212-222. PubMed ID: 30458583
[TBL] [Abstract][Full Text] [Related]
39. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.
Jiang W; Mahnken JD; He J; Mayo MS
Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial designs in the presence of stratification.
Tan SB; Machin D
Stat Med; 2006 Sep; 25(18):3220-2; author reply 3222-3. PubMed ID: 16906490
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
